Morgan Stanley lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $12 from $13 and keeps an Equal Weight rating on the shares. The firm update its model to reflect the strategic reprioritization to focus on BT5528 and next generation Bicycle conjugates, along with the workforce reduction of about 30%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics: Portfolio Refocus and Cost Cuts Extend Cash Runway, Strengthening Risk‑Reward and Supporting Buy Rating
- Bicycle Therapeutics price target lowered to $7 from $11 at RBC Capital
- Bicycle Therapeutics price target lowered to $36 from $44 at Oppenheimer
- Bicycle Therapeutics price target lowered to $8 from $12 at Citizens
- Bicycle Therapeutics price target lowered to $8 from $10 at Truist